跳至主要内容
临床试验/NCT01361412
NCT01361412已完成2 期

An Optional Research Study to Identify Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy in Subjects Already Enrolled in Clinical Study TR002

Circassia Limited2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2011年3月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
20
试验地点
2
主要终点
Identification of potential plasma biomarkers of response to peptide immunotherapy

研究概览

简要总结

The aim of the study is to identify changes in potential biomarkers after peptide immunotherapy for that may subsequently be developed as biomarkers that correlate with clinical efficacy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Enrolled in study TR002 but have not yet commenced dosing

排除标准

  • None; no criteria additional to TR002 exclusion criteria are applicable to this study

结局指标

主要结局

Identification of potential plasma biomarkers of response to peptide immunotherapy

时间窗: 6 months after start of dosing

Blood samples derived from the study will be submitted for proteomics analyses aimed at the identification of one or more plasma proteins whose concentration over the course of the study varies in relation to the treatment administered. The outcome will be determined on the basis of measurements from samples collected over a period commencing prior to treatment and ending 6 months following treatmen

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验